## CLAIMS

What is claimed is:

1. Use of levodopa in the manufacture of a medicament for treating OFF episodes in a Parkinson's Disease (PD) patient wherein levodopa is to be administered to the pulmonary system of the patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by at least 5 points as compared to placebo control.

2. Use of levodopa in the manufacture of a medicament for treating OFF periods in a Parkinson's Disease patient wherein levodopa is to be administered to the pulmonary system of the patient wherein the patient's UPDRS Part 3 score improves at least 5 to 12 points as compared to the patient's UPDRS score prior to administration of a fine particle dose (FPD) of levodopa.

3. Use of levodopa in the manufacture of a medicament for reducing the mean daily OFF time in a Parkinson's Disease patient wherein levodopa is to be administered to the pulmonary system of the patient at least twice a day wherein the patient's mean daily OFF time is reduced by at least one hour.

4. Use of levodopa in the manufacture of a medicament for treating a Parkinson's Disease patient wherein levodopa is to be administered to the pulmonary system of the patient, wherein the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by at least 8 points as compared to the patient's UPDRS score prior to administration.

5. Use of levodopa in the manufacture of a medicament for treating a Parkinson's Disease patient wherein levodopa is to be administered to the pulmonary system of the patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by at least 5 points as compared to placebo control.

6. The use of claim 1, wherein the patient's UPDRS Part 3 score is improved by at least 5 to 10 points as compared to placebo control.

7. The use of any one of claims 1, 2, 3, 4 or 5, wherein 30 mg to 60 mg fine particle dose (FPD) of levodopa is to be administered to the pulmonary system of the patient.

8. The use of any one of claims 1, 2, 3, 4 or 5, wherein 35 mg or 50 mg FPD of levodopa is to be administered to the patient.

9. The use of any one of claims 1, 2, 3 or 5, wherein the patient does not experience increased dyskinesis as compared to the level of dyskinesis prior to pulmonary administration of said levodopa.

10. The use of any one of claims 1, 2 or 3, wherein the patient has 3 to 4 OFF episodes a day.

11. The use of any one of claims 1, 2 or 3, wherein the patient has 4 to 8 hours of OFF episodes a day.

12. The use of any one of claims 1 or 5, wherein the patient's UPDRS Part 3 score is improved by at least 5 to 10 points as compared to placebo control within 60 minutes following administration of said FPD of levodopa.

13. The use of any one of claims 1, 2 or 5, wherein the contents of at least one capsule containing said FPD of levodopa is to be administered to the patient via inhalation.

14. The use of claim 13, wherein the contents of at least two capsules comprising said FPD of levodopa is to be administered to the patient via inhalation.

15. The use of claim 13, wherein the fine particle dose of levodopa is to be delivered from said at least one capsule to the pulmonary system by an inhalation device.

16. The use of claim 15, wherein the inhalation device is a dry powder inhaler (DPI) or a metered-dose inhaler (MDI).

17. The use of any one of claims 1, 2 or 5, wherein said administration occurs at the emergence of OFF symptoms.

18. The use of any one of claims 2 or 4, wherein the patient's UPDRS Part 3 score is improved by at least 8 points within 60 minutes following administration of said FPD of levodopa.

19. The use of claim 2, wherein the patient's UPDRS Part 3 score improves at least 8 points as compared to the patient's UPDRS score prior to administration of said FPD of levodopa.

20. The use of claim 3, wherein the patient's mean daily OFF time is reduced by at least 3 hours.